索拉非尼联合拓扑替康对比安慰剂联合拓扑替康治疗铂耐药卵巢癌(TRIAS):多中心、随机、双盲、安慰剂对照2期试验
TRIAS试验纳入铂耐药或铂难治性卵巢癌患者,随机接受拓扑替康联合索拉非尼或安慰剂,后续维持治疗。
要点
- 索拉非尼联合拓扑替康及维持治疗显著改善铂耐药卵巢癌的无进展生存期。
- 联合方案常见3-4级不良事件为白细胞减少、中性粒细胞减少和血小板减少。
- 索拉非尼组严重不良事件发生率59%,安慰剂组51%。
核心结论
- 索拉非尼联合拓扑替康并维持治疗在铂耐药卵巢癌中显示出统计学和临床显著的无进展生存期改善。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照2期试验,在德国20个中心进行,纳入185例患者,随机174例(索拉非尼85例,安慰剂89例)。
主要发现
- 最常见3-4级不良事件:白细胞减少(索拉非尼组69% vs 安慰剂组53%)、中性粒细胞减少(55% vs 54%)、血小板减少(28% vs 22%)。
- 严重不良事件发生率:索拉非尼组59%(49/83),安慰剂组51%(45/89);致死性事件分别为5%(4例)和8%(7例)。
关键数值与推荐
- 推荐条款:索拉非尼联合拓扑替康及维持治疗可作为铂耐药卵巢癌的潜在治疗选择,支持抗血管生成作为治疗骨架。
临床怎么用
- 对于铂耐药卵巢癌患者,可考虑索拉非尼联合拓扑替康方案,但需密切监测血液学毒性及手足皮肤反应等不良事件。
局限性
- 2期试验样本量有限;拓扑替康治疗为开放标签;需进一步3期试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. METHODS: We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotecan (1·25 mg/m2 on days 1-5) plus either oral sorafenib 400 mg or placebo twice daily on days 6-15, repeated every 21 days for six cycles, followed by daily maintenance sorafenib or placebo for up to 1 year in patients without progression. Investigators and patients were masked to allocation of sorafenib or placebo; topotecan treatment was open label. The primary endpoint was investigator-assessed progression-free survival, analysed in all patients who received at least one dose of study drug. This completed trial is registered with ClinicalTrials.gov, number NCT01047891. FINDINGS: Between Jan 18, 2010, and Sept 19, 2013, 185 patients were enrolled, 174 of whom were randomly assigned: 85 to sorafenib and 89 to placebo. Two patients in the sorafenib group had serious adverse events before treatment and were excluded from analyses. 83 patients in the sorafenib group and 89 in the placebo group started treatment. Progression-free survival was significantly improved with sorafenib versus placebo (hazard ratio 0·60, 95% CI 0·43-0·83; p=0·0018). Median progression-free survival was 6·7 months (95% CI 5·8-7·6) with sorafenib versus 4·4 months (3·7-5·0) with placebo. The most common grade 3-4 adverse events were leucopenia (57 [69%] of 83 patients in the sorafenib group vs 47 [53%] of 89 in the placebo group), neutropenia (46 [55%] vs 48 [54%]), and thrombocytopenia (23 [28%] vs 20 [22%]). Serious adverse events occurred in 49 (59%) of 83 sorafenib-treated patients and 45 (51%) of 89 placebo-treated patients. Of these, events were fatal in four patients (5%) in the sorafenib group (dyspnoea and poor general condition, septic shock, ascites and dyspnoea, and sigma perforation) and seven (8%) in the placebo group (pulmonary embolism in two patients, disease progression in two patients, and one case each of sepsis with fever, pleural effusion, and tumour cachexia). Sorafenib was associated with increased incidences of grade 3 hand-foot skin reaction (three [13%] vs 0 patients) and grade 2 alopecia (24 [29%] vs 12 [13%]). INTERPRETATION: Sorafenib, when given orally in combination with topotecan and continued as maintenance therapy, showed a statistically and clinically significant improvement in progression-free survival in women with platinum-resistant ovarian cancer. These encouraging results support the crucial role of antiangiogenesis as the treatment backbone in combination with chemotherapy, making this approach attractive for further assessment with other targeted strategies. FUNDING: Bayer, Amgen, and GlaxoSmithKline.
引用
- Chekerov R, Hilpert F, Mahner S, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018. PMID: 30100379. doi:10.1016/S1470-2045(18)30372-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。